MedTrace Logo

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 506

Last updated 2026-03-02

No results posted yet for this study

Summary

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Conditions

Interventions

DRUG

AZD5335

IV Antibody-drug conjugate

DRUG

Saruparib (AZD5305)

Oral PARP inhibitor

DRUG

Bevacizumab

IV Monoclonal antibody

DRUG

Carboplatin

IV Alkylating agent

DRUG

AZD9574

Oral PARP inhibitor

Sponsors & Collaborators

Principal Investigators

  • Funda Meric-Bernstam, MD · UT MD Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-05
Primary Completion
2028-01-06
Completion
2028-01-06
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • China
  • Germany
  • Israel
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05797168 on ClinicalTrials.gov